{"url":"https://newsforagent.com/news/2026-11-01/adherium-recurring-revenue-hailie-growth","markdown_url":"https://newsforagent.com/news/2026-11-01/adherium-recurring-revenue-hailie-growth.md","title":"Adherium Lifts Recurring Revenue 12.5% to $539,000","headline":"Adherium Posts Fifth Straight Record as Hailie Device Activations Reach 4,732","description":"Adherium's Q3 subscription revenue rose 12.5% to $539,000 with 1,033 Hailie devices shipped, as the company prepares value-based care contracts.","section":"Earnings & Results","published_at":"2026-11-01T22:47:25+00:00","modified_at":"2026-11-01T22:47:25+00:00","author":"News Desk","key_takeaways":["Adherium reported September-quarter recurring subscription revenue of $539,000, up 12.5% year-over-year and its fifth consecutive quarterly record.","The company shipped 1,033 Hailie devices and activated 900 in the quarter, lifting cumulative totals to 6,392 shipments and 4,732 activations.","More than 90% of Allergy Partners clinic locations now participate in Adherium's program, a network with an estimated 90,000 eligible asthma patients."],"companies":[{"name":"Adherium","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0005aiw/adherium","website":"http://www.adherium.com"},{"name":"Allergy Partners","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00098ul/allergy-partners","website":"https://www.allergypartners.com"},{"name":"Intermountain Health","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0002vfu/intermountain-health","website":"https://intermountainhealthcare.org"}],"source":{"publisher":"TradingView","title":"Adherium Lifts Recurring Revenue as Hailie Usage Expands","url":"https://www.tradingview.com/news/smallcaps:9a3cc4544094b:0-adherium-lifts-recurring-revenue-as-hailie-usage-expands/"},"other_sources":[],"tags":["Earnings & Results","Adherium","Allergy Partners","Intermountain Health"],"body_markdown":"[Adherium](https://akta.pro/company-profiles/0005aiw/adherium) reported September-quarter recurring subscription revenue of $539,000, up 12.5% year-over-year and its fifth consecutive quarterly record, according to [TradingView](https://www.tradingview.com/news/smallcaps:9a3cc4544094b:0-adherium-lifts-recurring-revenue-as-hailie-usage-expands/). The Australian digital health company, which sells the FDA-cleared Hailie Smartinhaler platform for remote monitoring of asthma and COPD patients, also recorded customer receipts of $544,000, up 33% from the preceding quarter.\n\n## Adherium's Hailie Shipments and Subscription Growth\n\nAdherium shipped another 1,033 Hailie devices and activated 900 during the three months, lifting cumulative totals to 6,392 shipments and 4,732 activations. Subscription revenue was 381% higher than in the September 2025 quarter, with billable revenue recognised as patients activate devices rather than when equipment is shipped.\n\nThe company has concentrated on improving early patient engagement through dedicated clinical support during the first seven days, more targeted outreach and analysis of longer-term retention. More than 90% of [Allergy Partners](https://akta.pro/company-profiles/00098ul/allergy-partners) clinic locations now participate in its program, providing access to a network with an estimated 90,000 eligible asthma patients.\n\nFollowing quarter-end, a partnership with Florida Lung, Asthma & Sleep Specialists extended the Hailie platform into Central Florida, while the group broadened its focus towards patients with severe respiratory disease. Adherium is using connected inhaler data, clinical support and patient engagement records generated by remote patient monitoring to build the operating evidence needed for outcomes-linked value-based care arrangements.\n\n\"We are building a strong foundation through our RPM platform, creating recurring revenue streams, proprietary patient data and a growing body of clinical evidence,\" interim chief executive officer John Perry said. \"Together, these assets position Adherium to pursue larger-scale, higher-value VBC contracts and partner with health systems and payers in ways that were not possible a few years ago.\"\n\n## Adherium's Funding and Allergy Partners Rollout\n\nAdherium raised up to A$7.52 million in February 2026 through a placement and accelerated non-renounceable entitlement offer, split between A$6.70 million institutional and up to A$0.82 million retail, to fund RPM channel growth and progression toward US value-based care contracts, according to akta.pro [company records](https://akta.pro/company-data). In November 2025, the company recorded a major US commercial milestone with the Allergy Partners rollout of the Hailie RPM platform across 110+ clinic locations serving 90,000+ asthma patients, with nearly 700 patients enrolled within six months.\n\n## Adherium's Path to the September Quarter\n\nIn June 2026, Adherium secured a US$1.65 million unsecured loan from shareholder Trudell Medical, with 12% annual interest and a September 2026 due date, to cover working capital while the company pursued share consolidation and R&D financing, Grafa reported. The following month, Adherium announced a leadership transition, appointing a new chief executive officer, AInvest reported. In October 2026, Adherium announced a partnership with Florida Lung, Asthma & Sleep Specialists to implement its Hailie platform for remote asthma and COPD monitoring, The future of trading reported.\n\n## Adherium's Medicare Rule and Management Changes\n\nAdherium is assessing proposed changes to US Medicare reimbursement for monitoring services, including patient eligibility, provider arrangements and payment rates. A final rule was expected in November and could differ from the July proposal. Mr Perry became interim chief executive officer in July, while Brad Wilson joined as chief financial officer in October.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}